Increased intensity of acute graft-versus-host disease after reduced-intensity bone marrow transplantation compared to conventional transplantation from an HLA-matched sibling in children

Inoue, Masami; Okamura, Takayuki; Yasui, Masayoshi; Sawada, Akihisa; Sakata, Naoki; Koyama, M.; Sakata, Akifumi; Takeshita, Yasufumi; Kouroki, Masahiko; Yagi, Keiko; Kawa, Keisei

doi:10.1038/sj.bmt.1705285

Cited by 4 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the lack of large and/or randomized studies about RIC and MAC [14], we reported that ovarian function was 81% (9/11) preserved after HSCT with RIC [8]. Although severe GVHD has been reported in RIC [15], no patients in our report have severe GVHD.…”

Section: Discussioncontrasting

confidence: 51%

Feasibility of reduced‐intensity allogeneic stem cell transplantation with imatinib in children with philadelphia chromosome‐positive acute lymphoblastic leukemia

Yamada

Yasui

Kondo

et al. 2013

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) in children is one of the highest-risk ALL groups. Improved outcome in combination with imatinib has been reported. However, intensive chemotherapy or myeloablative conditioning followed by hematopoietic stem cell transplantation (HSCT) can be associated with significant adverse late effects. We report a case series of five children with Ph + ALL underwent reduced-intensity allogeneic HSCT (RIST) after induction and consolidation in chemotherapy combined with imatinib. Four of the five patients remain first complete remission for a median of 3.1 years after RIST. These results are preliminary, but suggest the feasibility and effectiveness of RIST with imatinib.

show abstract

Section: Discussioncontrasting

confidence: 51%

Feasibility of reduced‐intensity allogeneic stem cell transplantation with imatinib in children with philadelphia chromosome‐positive acute lymphoblastic leukemia

Yamada

Yasui

Kondo

et al. 2013

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…More recently, a Japanese team published its experience comparing conventional matched sibling allo-BMT following myeloablative conditioning regimen to reduced-intensity allo-BMT in children with different solid tumors performed between 1994 and 2005. 11 There were five neuroblastoma patients in the conventional/myeloablative conditioning group; however, the paper focuses on the incidences of acute GVHD and details concerning the outcome of neuroblastoma patients were not provided.…”

Section: Conventional Allo-hsctmentioning

confidence: 99%

Allogeneic or haploidentical HSCT for refractory or relapsed solid tumors in children: toward a neuroblastoma model

Kanold

Paillard

Tchirkov

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

New concepts of allogeneic hematopoietic SCT (allo-HSCT) for neuroblastoma and other solid tumors do not rely on escalation of chemotherapy intensity and tumor load reduction but rather on a graft-vs-tumor effect. At this point, this is still an investigational and unusual application of allogeneic transplant, with 78 neuroblastoma patients reported to the European Group for Blood and Marrow Transplantation activity survey from 2002 to 2007 and less than 100 published cases. Two trends can be observed in the reviewed data: some teams have used allo-HSCT in children with refractory or progressive disease and significant tumor burden and other teams in children with CR, PR or minimal residual disease earlier in their disease process. Early studies of allo-HSCT in children with high-risk neuroblastoma suggest that this is a feasible approach that may improve outcome in this deadly disease. However, the proper timing for allo-HSCT during the disease course remains to be determined.

show abstract

Pediatric immunohematopoietic stem cell transplantation at a tertiary care center in Cape Town

Wood

Juritz

Havemann

et al. 2008

Hematology/Oncology and Stem Cell Therapy

View full text Add to dashboard Cite

Our analysis indicates that the standardized preparative regimen, coupled with a now well-established immunosuppressive regimen, is as effective in patients under 18 years of age as in adults. Our analysis also indicates that in a resource-scarce or developing country, it is mandatory to limit high-risk and relatively expensive procedures to active teams that enjoy international accreditation, whether these be in the state or private sector.

show abstract

Increased intensity of acute graft-versus-host disease after reduced-intensity bone marrow transplantation compared to conventional transplantation from an HLA-matched sibling in children

Cited by 4 publications

References 26 publications

Feasibility of reduced‐intensity allogeneic stem cell transplantation with imatinib in children with philadelphia chromosome‐positive acute lymphoblastic leukemia

Feasibility of reduced‐intensity allogeneic stem cell transplantation with imatinib in children with philadelphia chromosome‐positive acute lymphoblastic leukemia

Allogeneic or haploidentical HSCT for refractory or relapsed solid tumors in children: toward a neuroblastoma model

Pediatric immunohematopoietic stem cell transplantation at a tertiary care center in Cape Town

Contact Info

Product

Resources

About